A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection

Trial Profile

A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Posaconazole (Primary) ; Posaconazole (Primary) ; Voriconazole; Voriconazole
  • Indications Aspergillosis; Fusariosis; Zygomycosis
  • Focus Adverse reactions; Registrational
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 09 Sep 2015 Protocol has been amended to reduce treatment period from '>42 days- up to 168 days' to 'up to 84 days'
    • 09 Sep 2015 Planned number of patients changed from 90 to 112 as reported by ClinicalTrials.gov record
    • 09 Sep 2015 Planned End Date changed from 1 Jan 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top